Ayeskanta Mohanty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ayeskanta Mohanty has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Adityanarayan Mohapatra
Department of Biomedical Sciences and BioMedical Sciences Graduate Program (BMSGP), Chonnam National University Medical School, Gwangju, 61469, Republic of Korea
2 shared publications - In-Kyu Park
Department of Biomedical Sciences and BioMedical Sciences Graduate Program (BMSGP), Chonnam National University Medical School, Hwasun, Republic of Korea
2 shared publications - Aravindkumar Sundaram
Department of Biomedical Sciences and BioMedical Sciences Graduate Program (BMSGP) Chonnam National University Medical School Gwangju 61469 Republic of Korea
1 shared publication - Chang-Moon Lee
Chonnam National University
1 shared publication Chang‐Moon Lee
School of Healthcare and Biomedical Engineering Chonnam National University Yeosu 59626 Republic of Korea
1 shared publicationJiwon Seo
Department of Chemistry Gwangju Institute of Science and Technology Gwangju 61005 Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 1 April 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38, 103069
Carbohydrate polymer-based biomaterials for light-triggered Photo-Immunotherapy: Design strategies, immune mechanisms, and translational outlook
- 1 April 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38, 103069
Open AccessCarbohydrate polymer-based biomaterials for light-triggered Photo-Immunotherapy: Design strategies, immune mechanisms, and translational outlook
- 20 March 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (11) , e2500272
Programable Prodrug Nanomodulator Targets Tumor Redox Homeostasis Imbalance to Amplify Disulfidptosis and Immunogenic Pyroptosis for Breast Tumor Immunotherapy
Despite the great potential of photodynamic therapy (PDT), its success remains compromised by the abnormal redox homeostasis of tumor cells, which supports survival, growth, and resistance to oxidative therapeutic interventions by neutralizing reactive oxygen species (ROS). To overcome this barrier, a multifunctional prodrug nanomodulator (Pro@FLNC) is designed to induce disulfidptosis and immunogenic pyroptosis to trigger an antitumor immune response. Pro@FLNC features a prodrug core–shell structure where ursolic acid (UA) and Chlorin e6 (Ce6) are conjugated via a GSH‐responsive linker and encapsulated in a DSPE‐PEG‐FA lipid shell for enhanced stability, biocompatibility, and tumor‐specific targeting. Within the tumor microenvironment (TME), Pro@FLNC depletes intracellular GSH, disrupts redox homeostasis, and releases Ce6 and UA, triggering oxidative stress and mitochondrial dysfunction. These mechanisms amplify ROS production, promote lipid peroxidation, and initiate disulfidptosis, evidenced by increased SLC7A11 expression and F‐actin collapse. Elevated ROS levels and metabolic imbalance‐triggered disulfidptosis further activate immunogenic pyroptosis, releasing damage‐associated molecular patterns (DAMPs) that stimulate dendritic cell maturation and cytotoxic T‐cell activation. Together, Pro@FLNC reshapes the TME, reduces immunosuppressive cells, and promotes CD8+ T‐cell infiltration, effectively suppressing primary tumors and metastases. This programmed prodrug nanomodulator offers a promising strategy to enhance PDT and immunotherapy for advanced breast cancer.
- 20 March 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (11) , e2500272
Programable Prodrug Nanomodulator Targets Tumor Redox Homeostasis Imbalance to Amplify Disulfidptosis and Immunogenic Pyroptosis for Breast Tumor Immunotherapy
Despite the great potential of photodynamic therapy (PDT), its success remains compromised by the abnormal redox homeostasis of tumor cells, which supports survival, growth, and resistance to oxidative therapeutic interventions by neutralizing reactive oxygen species (ROS). To overcome this barrier, a multifunctional prodrug nanomodulator (Pro@FLNC) is designed to induce disulfidptosis and immunogenic pyroptosis to trigger an antitumor immune response. Pro@FLNC features a prodrug core–shell structure where ursolic acid (UA) and Chlorin e6 (Ce6) are conjugated via a GSH‐responsive linker and encapsulated in a DSPE‐PEG‐FA lipid shell for enhanced stability, biocompatibility, and tumor‐specific targeting. Within the tumor microenvironment (TME), Pro@FLNC depletes intracellular GSH, disrupts redox homeostasis, and releases Ce6 and UA, triggering oxidative stress and mitochondrial dysfunction. These mechanisms amplify ROS production, promote lipid peroxidation, and initiate disulfidptosis, evidenced by increased SLC7A11 expression and F‐actin collapse. Elevated ROS levels and metabolic imbalance‐triggered disulfidptosis further activate immunogenic pyroptosis, releasing damage‐associated molecular patterns (DAMPs) that stimulate dendritic cell maturation and cytotoxic T‐cell activation. Together, Pro@FLNC reshapes the TME, reduces immunosuppressive cells, and promotes CD8+ T‐cell infiltration, effectively suppressing primary tumors and metastases. This programmed prodrug nanomodulator offers a promising strategy to enhance PDT and immunotherapy for advanced breast cancer.